Diabetic nephropathy
Introduction
Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) [1, 2] . The incidence of end-stage kidney disease requiring chronic hemodialysis caused by diabetic nephropathy has increased rapidly during the last two decades worldwide, and morbidity associated with renal dysfunction involving chronic hemodialysis initiation remains greater than for those without diabetic nephropathy [3, 4] . In the pathogenesis of diabetic nephropathy, proteinuria, hyperlipidemia, hyperglycemia, and hypertension are established risk markers observed for progressive renal function loss [5] [6] [7] . Several clinical trials have been carried out using drugs such as angiotensin II receptor blockers (ARB) that improve these markers, and the results reported that such drugs conferred improvement in proteinuria and reduction of death and renal dysfunction rates for diabetic nephropathy with proteinuria [8] . However, there is still insufficient data concerning prognosis improvement for severe diabetic nephropathy accompanied by nephrotic syndrome. d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 2 4 1 -2 4 6 Some investigators have reported that low-density lipoprotein (LDL)-apheresis is effective in reducing proteinuria excretion in patients with steroid-resistant nephrotic syndrome, focal glomerulosclerosis, and diabetic nephropathy [9, 10] . In addition, LDL-apheresis removes various molecules such as oxidized LDL and inflammatory cytokines or chemokine and improves clinical laboratory parameters [11] [12] [13] [14] [15] [16] , and may reduce renal lesions. We found that LDL-apheresis reduced excretion of podocytes [17] , which have a key role in maintaining the integrity of the glomerular filtration barrier [18] [19] [20] . These results suggest that the effects of LDL-apheresis are exerted by removal of oxidative/inflammatory molecules and modulation of the inflammatory cascade in the glomerulus, and that it is a potentially effective treatment for diabetic nephropathy with severe proteinuria [17] . It is unknown whether these advantages of LDL-apheresis improve prognosis in terms of mortality or renal dysfunction. The purpose of the present study is to estimate, by means of a retrospective review, the prognosis of diabetic nephropathy with severe proteinuria treated with LDL-apheresis therapy.
Subjects
The present study is a single-center, retrospective review of diabetic nephropathy patients, consisting of an LDL-apheresis cohort and a control cohort with one subgroup. The LDLapheresis cohort (LDL-a) is composed of all patients who underwent LDL-apheresis therapy at Shin-Matsudo Central General Hospital, Chiba, Japan prior to 2010 (N = 20). The control cohort is composed of all patients at the same hospital who met the inclusion criteria of severe proteinuria !3 g/24 h from 2008 to 2010 and who were traceable (control-All; N = 55); a subgroup of the control cohort comprises the patients in control-All with severe proteinuria !5 g/24 h (control-mSP; N = 10) near to that of LDL-a.
Methods

Diagnosis criteria of diabetic nephropathy
Diabetic nephropathy was diagnosed based on the presence of following diabetic lesions: glomerulosclerosis such as nodular or diffuse (mesangial expansion), hyalinization of the renal arterioles, linear deposits of IgG in the glomerular basement membrane, and diffuse thickening of the glomerular basement on electron microscopy. If there is no renal biopsy data of diabetic lesions, as a substitute by evaluation of clinical laboratory tests: clinical syndrome characterized by persistent albuminuria (>300 mg/24 h) (also referred to as macroalubuminuria or proteinuria), a steady decline in glomerular filtration rate (GFR), and elevated blood pressure [21] .
Clinical parameters and laboratory measurements
Body mass index was calculated as body weight (in kilograms) divided by height (in meters) squared. Hypertension was defined according to WHO criteria (systolic blood pressure [BP] > 160 mmHg and/or diastolic BP > 95 mmHg, or on antihypertensive treatment at baseline). Hypercholesterolemia was defined according to the criteria total cholesterol >220 mg/dL and LDLcholesterol >140 mg/dL. Stroke was defined as a reported medical history of cerebral infarction or cerebral hemorrhage. Coronary artery disease (CAD) was defined as a reported history of myocardial infarction, angina, percutaneous coronary intervention, or coronary artery bypass graft. Retinopathy and neuropathy were determined from the reported medical history.
Samples of blood and urine taken at routine clinical checkups were analyzed at baseline for creatinine, total protein, LDL-cholesterol, and HbA1c and for protein and liver-type fatty acid binding protein (L-FABP), respectively.
Outcomes assessment
Baseline for LDL-a and the control cohorts is defined as the day of starting LDL-apheresis therapy or meeting the inclusion criteria, respectively. Surveillance for major events included screening hospitalization history until 3 years from baseline. A major event was defined as any incident of stroke, CAD, renal dysfunction, or death. Renal dysfunction was defined as doubling of serum creatinine concentration, chronic hemodialysis initiation, or renal transplantation [8] . Doubling of serum creatinine concentration was defined as the first serum creatinine concentration that was twice the baseline, as confirmed by a second serum creatinine concentration obtained at about 3 months after the initial doubling.
2.4.
LDL-apheresis LDL-apheresis was performed using hollow polysulfone fibers (Sulflux; Kaneka Co. Ltd., Osaka, Japan) as the plasma separator and a dextran sulfate cellulose column (Liposorber; Kaneka Co. Ltd., Osaka, Japan) as the LDL absorber. About 3000 to 4000 mL of plasma (60 mL/kg body weight) was treated for 3 h in each apheresis session [9] . LDL-apheresis was performed in series twice a week for 3-6 weeks (6-12 times per patient).
Statistical analysis
Data are expressed as the mean AE SD. Differences in baseline characteristics between two cohorts were evaluated by the chisquare test, or Fisher's exact test for categorical variables or Student's t test for continuous variables. Survival, major event free, renal dysfunction free, and death/renal dysfunction free rates for the cohorts were estimated by the Kaplan-Meier method and analyzed by log-rank tests [22] . Prognostic factors of severe diabetic nephropathy were estimated by logistic regression analysis. Statistical analyses were performed using SPSS version 16.0.
Results
Characteristics of each cohort
Baseline characteristics of LDL-a and the control cohorts are listed in Table 1 , and proteinuria (6.8 AE 2.9 g/24 h, P < 0.001) were significantly more severe in LDL-a than control-mSP. In LDL-a cohort, LDL cholesterol levels were significantly decreased after LDL-apheresis treatment (from base line: 227.1 AE 33.0 mg/dL to after: 88.0 AE 15.5 mg/dL; P < 0.001) and restored to normal range. Life-threatening history or concomitant diseases such as stroke (P < 0.001), coronary artery disease (CAD; P < 0.001), and heart failure (P < 0.001) were significantly higher in LDL-a than control-All; however, there were no differences in lifethreatening history or concomitant diseases between LDL-a and control-mSP.
The frequency of use of anti-hypertension drugs, ACE inhibitors and ARB, and insulin were almost the same in each cohort. On the other hand, the frequency of statin use was significantly higher in LDL-a (100%) than control-All (33%; P < 0.001) and control-mSP (60%; P = 0.008).
Major events
Major events for LDL-a and the control cohorts are listed in Table 2 . Major events were observed for 14 patients (70%) in LDL-a, 35 patients (64%) in control-All, and 10 patients (100%) in control-mSP. Incidence of CAD was significantly higher in LDL-a than control-All (P = 0.002). Mortality was significantly higher (P = 0.03) in control-All (N = 15; 27%) than LDL-a (N = 1; 5%). The most common cause of death in control-All was heart failure, followed by stroke and renal failure. In the renal dysfunction component, incidence of serum creatinine doubling and chronic hemodialysis initiation were significantly higher in control-All than in LDL-a (P = 0.001 and P = 0.006, respectively).
Outcome Analysis
Survival, renal dysfunction free, death/renal dysfunction free, and major event free rates were estimated by the Kaplan-Meier method and analyzed by log-rank tests. The survival rate was significantly higher in LDL-a than control-All (x 2 = 4.05 [P = 0.04] vs. x 2 = 2.72 [P = 0.1] at 2 years follow-up) ( Fig. 1) ; however, there was no significant difference compared with control-mSP (x 2 = 2.83; P = 0.09) (Fig. 1) . The renal dysfunction free rate was significantly higher in LDL-a than control-mSP (x 2 = 28.4 [P < 0.001] vs. x 2 = 30.5 [P < 0.001] at 2 years follow-up) (Fig. 2 ). There was no significant difference between LDL-a and control-All (x 2 = 3.00; P = 0.08), but a difference was observed at 2 years follow-up (x 2 = 7.26; P = 0.007). The death/renal dysfunction free rate was also significantly higher in LDL-a than control-All (x 2 = 4.50 [P = 0.03] vs. x 2 = 6.91 [P = 0.009] at 2 years follow-up); furthermore, there was a significant difference between LDL-a and control-mSP (x 2 = 28.02 [P < 0.001] vs. x 2 = 27.68 [P < 0.001] at 2 years follow-up) ( Fig. 3 ). On the other hand, the major event free rate showed no significant difference between LDL-a and control-All (x 2 = 0.43; P = 0.5) (figure not shown).
To estimate the independent prognostic factors of severe diabetic nephropathy, baseline variables were compared for death, renal dysfunction, and death/renal dysfunction in control-All. Age, BMI, serum creatinine, total protein, and LDL-cholesterol were identified as candidates, and LDL-cholesterol was finally estimated by multiple logistic regression analysis as the common independent prognostic factor for death (OR, 0.96; 95% CI [0.93-1.00]; P = 0.03), renal dysfunction (OR, 0.93; 95% CI [0.88-0.99]; P = 0.03), and death/renal dysfunction (OR, 0.94; 95% CI [0.88-1.00]; P = 0.04) ( Table 3 ). In addition, total protein was also an independent prognostic factor for death/renal dysfunction (OR, 50.0; 95% CI [2.52-989.8]; P = 0.01). In order to examine the influence for the prognosis of statins having an LDL-cholesterol lowering effect, control-All was divided into two groups of patients who met the respective inclusion criteria of with or without the initiation of statin therapy, and survival and death/renal dysfunction free rates were estimated by the Kaplan-Meier method and analyzed by log-rank tests. Statin therapy was initiated for 18 patients and not initiated for 37. There were no significant differences between the groups with or without the initiation of statin therapy in terms of the survival rate (x 2 = 0.11; P = 0.7), renal dysfunction free rate (x 2 = 0.19; P = 0.7), or death/renal dysfunction free rate (x 2 = 0.31; P = 0.6) (figure not shown). N = 55) , and dashed-gray line denotes the cohort with more severe proteinuria, control-mSP (N = 10). Renal dysfunction free rate was significantly higher in LDL-a than control-mSP (x 2 = 28.4; P < 0.001). N = 55) , and dashed-gray line denotes the cohort with more severe proteinuria, control-mSP (N = 10). Death/renal dysfunction free rate was significantly higher in LDL-a than control-All (x 2 = 4.50; P = 0.03) and control-mSP (x 2 = 28.02; P < 0.001). N = 55) , and dashed-gray line denotes the cohort with more severe proteinuria, control-mSP (N = 10). Survival rate was significantly higher (x 2 = 4.05; P = 0.04) in LDL-a than control-All.
4.
Discussion
Diabetic nephropathy is a potentially life-threatening condition having a poor prognosis, with a high risk of progression to end-stage renal failure. Although there have been several reports noting short-term recovery of clinical symptoms or parameters with LDL-apheresis therapy, there is insufficient data or evidence about its long-term effects, such as its prognostic effect. In this retrospective study, we followed up patients with severe diabetic nephropathy in the LDL-a and control cohorts and examined the long-term effects of LDL-apheresis.
According to the baseline characteristics and medical history, the disease condition of LDL-a was more severe than control-All, and the condition of control-mSP was more severe than control-All and near that of LDL-a but not at the same level. Despite the difference in the degree of disease severity, survival and the renal dysfunction free and death/renal dysfunction free rates were significantly higher in LDL-a than the control cohorts. Furthermore, LDL-a cohort compared with Reduction in End Points in Noninsulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study subgroup data (albuminuria >3.0 g/g subgroup; 289 patients) [7] . Baseline data were similar with LDL-a cohort in this study (age: 58.1 AE 7.8 vs. 59.3 AE 13.8, serum creatinine: 2.1 AE 0.5 mg/dL vs. 1.9 AE 0.9 mg/dL as described 170.6 AE 81.3 mol/L in manuscript, eGFR: 33.8 AE 11.0 mL/min/1.73 m 2 vs. 35.1 AE 17.7 mL/min/ 1.73 m 2 , proteinuria: 8.9 AE 4.3 g/day vs. 10.5 AE 2.1 g/day; albuminuria >3.0 g/g subgroup vs. LDL-a cohort, respectively). On the other hand, obvious difference was observed in the prognosis of these cohorts. The death/renal dysfunction (defined as doubling of serum creatinine concentration, chronic hemodialysis initiation, or renal transplantation) rate were probably 60% in albuminuria >3.0 g/g subgroup and 5% in LDL-a cohort for 2 years, and probably 80% in albuminuria >3.0 g/g subgroup and 30% in LDL-a cohort for 3 years, respectively. LDL-a cohort was small, but this comparison result was very impressive and suggested the possibility of LDL apheresis therapy for severe diabetic nephropathy patients.
A survey of the prognostic factors identified LDLcholesterol as an estimated common independent factor for diabetic nephropathy with severe proteinuria. Furthermore, despite the fact that statin also reduces the serum LDLcholesterol level, statin administration had no influence on the prognosis. LDL-apheresis is considered to directly focus on the therapeutic target LDL-cholesterol, and may be a promising therapy for diabetic nephropathy with severe proteinuria.
On the other hand, although the survival rate was significantly different between LDL-a and control-All, there was no significant difference from the more severe cohort, control-mSP, as noted above. Similarly, despite the fact that LDLapheresis therapy reduces serum LDL-cholesterol, which is one of the risks for CAD, the incidence of CAD was higher in LDL-a than control-All. These trends are thought to be due to the small size of the LDL-a and control-mSP cohorts. However, statistical analysis confirmed the possibilities which LDLapheresis contributes to improvement in avoiding death and renal dysfunction in severe diabetic nephropathy patients in the nephrotic syndrome state.
In the pathogenesis of diabetic nephropathy, proteinuria is one of the established risk markers observed for progressive renal function loss [5, 6] . Renal function loss is exacerbated by collapse of the glomerular filtration barrier structure. Podocytes, which have a key role in maintaining the integrity of the glomerular filtration barrier, are also a clinically effective marker and linked to the development of proteinuria [9, 11, 12] . We previously reported that LDL-apheresis effectively reduces podocyte excretion and ameliorates renal dysfunction in patients with nephrotic syndrome caused by diabetic nephropathy, and suggested the possibility that LDL-apheresis maintains renal function by protecting podocytes [17] . Some investigators have reported a relationship between hyper LDL-cholesterolemia and glomerular injury in inflammation [23, 24] . With oxidative modifications of the major cholesterolcarrying lipoproteins, the LDLs, the oxidized LDLs are taken up by the scavenger receptor of macrophages, which leads to the formation of foam cells and thrombus, and stimulates monocytes to secrete various cytokines, thus accelerating inflammation [11] . According to the results of several studies showing that LDL-apheresis removes various molecules such as oxidized LDL, TNF-alfa, IL-6, VEGF, and MCP-1, among the inflammatory cytokines or chemokines [16] , the clinical efficacy of LDL-apheresis is considered to be exerted by the removal of oxidative/inflammatory molecules and modulation of the inflammatory cascade in the glomerulus. Therefore, LDL-apheresis is a promising therapy that rescues renal function by maintenance of the glomerular basement membrane/podocytes, and contributes to improving the prognosis of diabetic nephropathy with severe proteinuria.
In this study, all patients in the LDL-a cohort received only one course of six to 12 sessions of LDL-apheresis therapy, and drug medication such as statin, ARB, and insulin for diabetic nephropathy were started or continued. Renal function maintenance was higher in LDL-a compared with the control cohorts, and LDL-apheresis therapy actually delayed the d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 2 4 1 -2 4 6 progression of ESRD or initiation of chronic hemodialysis. However, although the renal function maintenance rate remained high until approximately day 900 after LDL-apheresis, the rate then fell slightly in LDL-a. These processes may suggest that LDL-apheresis is a therapy that should be considered not only once, but twice or more times, adjusting the treatment to the patient's condition.
In this study, we found the possibilities which LDL-apheresis contributes to survival extension and renal function maintenance in severe diabetic nephropathy patients. However, this study has some limitations such as retrospective design and performed in one hospital, we think it is not enough as evidence. In the future, a prospective study will be carried out, and we expect to accumulate more evidence to establish the most suitable therapy.
